AFFILIATIONS
1 Labcorp, San Diego, California, United States
2 Labcorp, San Diego, California, United States
3 Labcorp, San Diego, California, United States
4 Labcorp, San Diego, California, United States
5 Labcorp, San Diego, California, United States
6 Labcorp, San Diego, California, United States
7 Labcorp, San Diego, California, United States
8 Labcorp, San Diego, California, United States
9 Labcorp, Durham, North Carolina, United States
10 Labcorp, San Diego, California, United States
11 Cleveland Clinic, Cleveland, Ohio, United States
12 Labcorp, Westborough, Massachusetts, United States
13 Labcorp, Durham, North Carolina, United States
14 Labcorp, Durham, North Carolina, United States
15 Labcorp, Durham, North Carolina, United States, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States
16 Labcorp, Durham, North Carolina, United States
17 Labcorp, Metropark, New Jersey, United States
18 Labcorp, Burlington, North Carolina, United States
19 Labcorp, Burlington, North Carolina, United States
20 Labcorp, San Diego, California, United States
21 Labcorp, Durham, North Carolina, United States, Labcorp, San Diego, California, United States
22 Labcorp, San Diego, California, United States
ABSTRACT
Introduction
Biallelic TP53 mutations define subtypes of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with dismal prognosis. Biallelic status is frequently inferred from short read NGS panel clinical testing. By convention, small sequencing mutations (single nucleotide variants or insertion/deletions) in TP53 are considered biallelic if there are multiple mutations in TP53 gene (TP53multi), or if there is a single mutation with variant allele frequency (VAF) >55%. Evidence for TP53multi being biallelic comes from the poor prognosis of TP53multi compared to TP53 single hit mutations. It is assumed that the poorer outcome is due to loss of both copies of TP53. Determining whether two TP53 mutations are biallelic using short read NGS requires phasing haplotypes. Sufficient resolution to phase haplotypes using short read NGS generally requires complete sequencing of exons and introns, but limitations in ability to phase persist. In this study, we sequenced captured libraries from samples with TP53multi using long read NGS to confirm the presence of biallelic TP53. TP53multi was initially detected by short read NGS clinical testing of hematological oncology patients. We found that, of the 58 TP53multi samples in this study, 56 were confirmed as being biallelic, with the remaining 2 samples showing evidence of separate TP53 single-hit clones.
Methods
TP53multi samples were identified using a 50-gene short read NGS genomic profiling Laboratory Developed Test. For long read NGS(PacBio®), libraries were generated from approximately 350 ng of the same extracted DNA that was used for short read NGS and exons were captured with a 2x tiled 141-gene panel according to manufacturer’s protocol (Twist Bioscience, San Francisco, CA). Captured libraries were sequenced on a PacBio Sequel II to at least 150x circular consensus sequencing (CCS) read coverage in the TP53 gene with a mean read length of 4390 bp. Bam files were reviewed manually using integrated genome viewer (IGV). TP53multi were considered biallelic if 0 reads contained both mutant alleles in cis and if at least 5 reads containing a TP53 mutation showed wild type for the second mutation position suggesting a mutation in trans. Information from germline mutation alleles were also used to confirm biallelic TP53 when present between the two TP53 mutations.
Results
In our reference laboratory over a 12-month period, 6.3% of myeloid patient samples analyzed with short read NGS were TP53 mutated. Of these samples, 22.3% were TP53multi and 28.1% were TP53 with VAF>55%. We selected 58 recent TP53multi samples for long read NGS analysis. The 58 TP53multi samples showed 100% concordance for all TP53 mutations between short and long read NGS with VAF ranging from 5.4% to 77.9%. The distance between TP53multi mutations meant that the read lengths generated were sufficient to determine biallelic status without advanced daisy chain or other analysis methods. 56 of 58 TP53multi samples showed evidence of biallelic mutations in trans. For 2 of the samples, TP53 variants appeared on the same haplotype, but never the same CCS read, indicating that the mutations may not be truly biallelic, nor in cis, but rather may occur in separate clones. To determine if these 2 samples were biallelic due to TP53 mutation plus TP53 loss, they were taken through an additional short read NGS panel to determine the presence of a potential TP53 copy number variant. No additional TP53 loss was observed. We cannot rule out copy number neutral loss of heterozygosity (CNN-LOH) for either of these clones, but these results suggest that a small percentage of patients with TP53multi are not TP53 biallelic.
Conclusion
56 of 58 samples showed TP53 mutations in trans supporting the assumption that TP53multi are biallelic in the majority of cases. The current treatment guidelines recommend aggressive treatment for TP53multi and these findings support the current treatment approaches except for a small percentage of patients (2/58; 3.4%). Long read NGS was performed without special considerations for DNA extraction or capture panel design. This study suggests that long read NGS can readily be used to confirm mutations that are challenging for short read NGS providing a more comprehensive analysis of myeloid patient mutation status. However, single cell sequencing is most likely the optimal method to truly determine TP53 biallelic status.
DISCLOSURES
Grant Hogg, MS: Labcorp - Current Employment